Please check your internet connection and try again.
## Ecospirin (Aspirin Enteric-Coated)
### Overview
Ecospirin is an enteric-coated formulation of aspirin, a non-steroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory, and antipyretic properties. The enteric coating is designed to delay the release of aspirin until it reaches the small intestine, potentially reducing gastric irritation.
### Primary Indications
* **Cardiovascular Prevention:** Primary and secondary prevention of cardiovascular events (e.g., myocardial infarction, stroke) in patients with established cardiovascular disease, those at high risk, or after specific procedures like coronary artery bypass grafting or percutaneous coronary intervention.
* **Rheumatologic Conditions:** Management of pain and inflammation associated with conditions like rheumatoid arthritis and osteoarthritis.
* **Analgesia and Antipyresis:** Relief of mild to moderate pain and reduction of fever.
### Adult Dosing
Dosing varies significantly based on indication:
* **Cardiovascular Prevention:**
* **Secondary Prevention:** 75 mg to 150 mg orally once daily. Higher doses (e.g., 325 mg) may be used initially in certain acute settings but typically transitioned to lower maintenance doses.
* **Primary Prevention:** 75 mg to 100 mg orally once daily. Use in primary prevention is individualized based on cardiovascular risk assessment and bleeding risk.
* **Post-PCI/CABG:** Dosing and duration depend on specific guidelines and procedural factors, often starting with higher doses and transitioning to maintenance.
* **Rheumatologic Conditions:** 325 mg to 650 mg orally every 4 to 6 hours as needed, or higher doses up to 4000 mg per day in divided doses under medical supervision. Doses for inflammation are generally higher than for cardiovascular prevention.
* **Analgesia/Antipyresis:** 325 mg to 650 mg orally every 4 to 6 hours as needed. Maximum daily dose typically 4000 mg.
**Note:** Specific dosing regimens for cardiovascular indications should adhere to current guidelines (e.g., ACC/AHA).
### Pediatric Dosing
Aspirin is generally **not recommended** in children and adolescents (<19 years) due to the risk of Reye's syndrome, particularly during viral infections like influenza or chickenpox. If aspirin is deemed absolutely necessary for specific indications (e.g., Kawasaki disease), dosing is based on weight and should be managed by a specialist.
### Dose Adjustments
* **Renal Impairment:** Use with caution. High doses can exacerbate renal dysfunction. Dose reduction may be considered in severe impairment, but specific guidelines are limited.
* **Hepatic Impairment:** Use with caution. Monitor liver function.
* **Elderly:** Increased risk of gastrointestinal bleeding and other adverse effects. Use the lowest effective dose.
### Contraindications
* Known hypersensitivity to aspirin, salicylates, or NSAIDs.
* Asthma, urticaria, or other allergic-type reactions precipitated by aspirin or other NSAIDs.
* Active peptic ulcer disease or active gastrointestinal bleeding.
* Bleeding disorders (e.g., hemophilia, von Willebrand disease).
* Severe hepatic or renal impairment.
* Children and adolescents (<19 years) with viral infections due to risk of Reye's syndrome.
### Adverse Effects
* **Gastrointestinal:** Dyspepsia, nausea, vomiting, abdominal pain, heartburn, **serious GI bleeding, ulceration, perforation**.
* **Hematologic:** Increased bleeding time, bruising, petechiae, **hemorrhage**.
* **Hypersensitivity:** Bronchospasm, rhinitis, urticaria, angioedema.
* **Ototoxicity:** Tinnitus, hearing loss (often dose-related).
* **Renal:** Acute kidney injury, interstitial nephritis.
* **Hepatic:** Elevated liver enzymes, hepatic dysfunction.
* **Reye's Syndrome:** In children and adolescents with viral infections.
### Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Increased risk of bleeding. Concurrent use requires careful monitoring or avoidance.
* **Other NSAIDs:** Increased risk of GI toxicity and bleeding.
* **Corticosteroids:** Increased risk of GI ulceration and bleeding.
* **Selective Serotonin Reuptake Inhibitors (SSRIs) / Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs):** Increased risk of bleeding.
* **Methotrexate:** Increased methotrexate levels and toxicity.
* **Uricosuric agents (e.g., probenecid):** Decreased efficacy of uricosuric agents.
* **Alcohol:** Increased risk of GI bleeding.
* **Antihypertensives:** May reduce the efficacy of some antihypertensive agents.
### Monitoring
* **Signs of GI bleeding:** Melena, hematemesis, abdominal pain.
* **Signs of bleeding elsewhere:** Easy bruising, prolonged bleeding from cuts, epistaxis.
* **Renal and hepatic function:** Particularly with long-term use or in patients with pre-existing impairment.
* **Tinnitus or hearing changes:** May indicate excessive dosage.
### Clinical Pearls
* The enteric coating is designed to bypass the stomach; however, aspirin can still be absorbed systemically and cause GI side effects. Advise patients to swallow tablets whole without crushing or chewing.
* For acute cardiovascular events (e.g., suspected MI), immediate-release (non-enteric coated) aspirin is typically preferred for faster absorption.
* Regular use of aspirin for cardiovascular protection significantly increases bleeding risk. The benefit must outweigh the risk.
* Discontinue aspirin at least 5-7 days prior to elective surgery to minimize bleeding risk, unless otherwise directed by a physician.
* Avoid aspirin in patients with a history of salicylate-induced asthma or nasal polyps.
***
*Disclaimer: This information is intended for clinical use and does not replace the official prescribing information. Always consult the most current drug monograph and relevant clinical guidelines before making therapeutic decisions.*
